NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified and
transduced with a lentiviral vector expressing a second-generation chimeric antigen
receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19,
with potential immunostimulating and antineoplastic activities. Upon administration,
obecabtagene autoleucel target and bind to CD19-expressing tumor cells. This results
in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and
tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface
antigen overexpressed in B-cell lineage tumors. The CAT-41BBz CAR has a faster off-rate
compared with FMC63-41BBz CAR. This may minimize cytokine release and reduce toxicities,
and enhance persistence of the CAR T-cells.;